Gujarat Themis Biosyn Ltd.
NSE: GUJTHEM.NS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- National Stock Exchange of India
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Sachin Dinesh Patel
- Employees
- 221
- Headquarters
- Mumbai, India
- IPO year
- 2025
- Market cap
- ₹43.4B
- Website
- https://www.gtbl.in
Loading GUJTHEM…
Loading profile data…Frequently asked questions about GUJTHEM
What does Gujarat Themis Biosyn Ltd. (GUJTHEM.NS) do?
Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O for the treatment...
Where does GUJTHEM.NS trade?
Gujarat Themis Biosyn Ltd. (GUJTHEM.NS) trades on the National Stock Exchange of India.
What sector is GUJTHEM.NS in?
Gujarat Themis Biosyn Ltd. (GUJTHEM.NS) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Gujarat Themis Biosyn Ltd.?
Sachin Dinesh Patel is the chief executive officer of Gujarat Themis Biosyn Ltd. (GUJTHEM.NS).
Where is Gujarat Themis Biosyn Ltd. headquartered?
Gujarat Themis Biosyn Ltd. is headquartered in India.
Does GUJTHEM.NS pay a dividend?
Yes — Gujarat Themis Biosyn Ltd. (GUJTHEM.NS) paid a trailing twelve-month dividend of INR 0.67 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did GUJTHEM.NS go public?
Gujarat Themis Biosyn Ltd. (GUJTHEM.NS) completed its initial public offering in 2025.